- Home
- FINW vs SPRO Comparison
FINW vs SPRO Comparison
Compare FINW & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- SPRO
- Stock Information
- Founded
- FINW 1999
- SPRO 2013
- Country
- FINW United States
- SPRO United States
- Employees
- FINW N/A
- SPRO N/A
- Industry
- FINW Commercial Banks
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- SPRO Health Care
- Exchange
- FINW Nasdaq
- SPRO Nasdaq
- Market Cap
- FINW 196.2M
- SPRO 164.4M
- IPO Year
- FINW 2021
- SPRO 2017
- Fundamental
- Price
- FINW $15.67
- SPRO $2.91
- Analyst Decision
- FINW Buy
- SPRO Buy
- Analyst Count
- FINW 4
- SPRO 4
- Target Price
- FINW $20.75
- SPRO $5.00
- AVG Volume (30 Days)
- FINW 76.0K
- SPRO 1.6M
- Earning Date
- FINW 07-24-2025
- SPRO 08-04-2025
- Dividend Yield
- FINW N/A
- SPRO N/A
- EPS Growth
- FINW N/A
- SPRO N/A
- EPS
- FINW 0.91
- SPRO N/A
- Revenue
- FINW $72,056,000.00
- SPRO $44,584,000.00
- Revenue This Year
- FINW $38.17
- SPRO N/A
- Revenue Next Year
- FINW $18.44
- SPRO N/A
- P/E Ratio
- FINW $17.21
- SPRO N/A
- Revenue Growth
- FINW 7.66
- SPRO N/A
- 52 Week Low
- FINW $10.29
- SPRO $0.51
- 52 Week High
- FINW $20.94
- SPRO $3.09
- Technical
- Relative Strength Index (RSI)
- FINW 66.33
- SPRO 71.62
- Support Level
- FINW $13.81
- SPRO $2.79
- Resistance Level
- FINW $14.37
- SPRO $3.03
- Average True Range (ATR)
- FINW 0.55
- SPRO 0.12
- MACD
- FINW 0.22
- SPRO -0.08
- Stochastic Oscillator
- FINW 89.53
- SPRO 43.75
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.